Q3 2025: NAV up 3.6% as Beacon’s financing lights the way
Syncona has posted a tidy quarter. Net assets rose to £1,058.2 million, with NAV per share up 3.6% to 173.9p. The Life Science Portfolio – the core engine of value – grew 5.0% to £840.1 million, helped by a 20% uplift at Beacon Therapeutics after its oversubscribed Series C round and a firmer share price at Autolus.
Management’s tone is upbeat. They see public biotech stabilising and capital beginning to flow back into private names. Importantly for shareholders, Syncona reiterates that potential portfolio progress could support the return of a minimum of £250 million to investors under its proposed new Investment Objective and Policy. That proposal isn’t approved yet, but it is a clear marker of intent.
What moved the numbers this quarter
- Beacon Therapeutics raised $75 million in an oversubscribed Series C led by Goldman Sachs Alternatives, validating the story and catalysing a 20% valuation uplift.
- Autolus saw share price appreciation as it ramps its US launch of AUCATZYL® (obe-cel).
- Syncona deployed £52.6 million, largely into late-stage assets and Resolution. The capital pool remains robust at £218.1 million to back upcoming milestones.
- Over the nine months to 31 December, NAV per share is up 1.8% with the Life Science Portfolio up 3.3%.
Quick scorecard
| Group NAV | £1,058.2 million |
| NAV per share | 173.9p |
| Q3 NAV per share return | 3.6% |
| Life Science Portfolio valuation | £840.1 million |
| Life Science Portfolio quarterly return | 5.0% |
| Capital pool (31 Dec 2025) | £218.1 million |
| Capital deployed in quarter | £52.6 million |
| Nine-month NAV per share return | 1.8% |
| Portfolio mix | 85% in commercial, late-stage and clinical companies |
Clinical and financial progress across the portfolio
Syncona has been hands-on with its core holdings, and there’s been steady execution:
- Beacon reported longer-term positive data from two Phase II trials, SKYLINE (36 months) and DAWN (9 months).
- iOnctura completed patient enrolment in two Phase II studies in uveal melanoma and non-small cell lung cancer.
- Resolution published new clinical data supporting its Regenerative Macrophage Therapy’s potential anti-inflammatory and anti-fibrotic effects in cirrhosis.
- Spur is initiating its Phase III programme in Gaucher disease, and Purespring is initiating a Phase I/II programme in IgA nephropathy – both companies are opening sites.
Funding window reopens? Beacon’s oversubscribed raise
Beacon’s $75 million Series C – led by Goldman Sachs Alternatives – is the standout. Syncona committed $24.5 million, and the financing drove a 20% valuation uplift for Beacon. That’s meaningful in a market where many private biotech rounds have been tough to price.
On cash outlay, Syncona invested £10.3 million in Beacon’s Series C during the quarter. In total, it put £21.5 million into Beacon since 30 September 2025, including £11.2 million as part of tranche two of the Series B. This is a classic Syncona playbook: lean in when external validation and clinical progress align.
Eight value inflection points in three years – four due in 2026
Syncona maps eight key value events across its strategic portfolio over the next three years, with four expected in calendar 2026. These are the catalysts that could drive NAV higher – but they carry the usual clinical and market risks.
- Autolus (on the market) – further commercial traction in CY2026 following the US launch of AUCATZYL® (obe-cel).
- Beacon – pivotal VISTA data in XLRP due H2 CY2026.
- iOnctura – Phase II uveal melanoma readout in H2 CY2026.
- Resolution – interim Phase I/II data in end-stage liver disease in H2 CY2026.
Quell is the notable change. Its key inflection slips to CY2027 as it prioritises QEL-005 in rheumatologic autoimmune diseases (RA/SSc), with the CHILL Phase I/II study expected to start this year. The Phase I/II LIBERATE study in liver transplantation is paused to concentrate capital on QEL-005, which management believes could represent a larger commercial opportunity. Not ideal on timing, but the company cites technical learnings that de-risk QEL-005.
Capital allocation: focused, selective, and still well funded
Deployment was disciplined and skewed to later-stage exposure. Syncona says 85% of capital went into late-stage clinical companies and Resolution, aligning with the proposed new Capital Allocation Policy.
- Beacon – £10.3 million into the Series C round during the quarter.
- NewCo (immunology) – £4.5 million as a selective new opportunity.
- ALTX Therapeutics – £3.6 million via Slingshot, targeting cancers that exploit the Alternative Lengthening of Telomeres pathway.
With £218.1 million of capital at period end, Syncona states it is funded to deliver the identified value inflection points. That cash buffer matters if markets wobble or trials take longer.
Where the NAV is concentrated
The portfolio remains concentrated in a handful of substantial positions, which is typical for Syncona’s strategy. Here are several of the larger holdings at 31 December 2025:
| Spur | £196.0 million | 18.5% of NAV |
| Beacon Therapeutics | £176.3 million | 16.7% of NAV |
| Quell | £81.9 million | 7.8% of NAV |
| Resolution | £71.3 million | 6.7% of NAV |
| Purespring | £53.4 million | 5.0% of NAV |
| OMass | £49.7 million | 4.7% of NAV |
| Autolus | £42.6 million | 4.0% of NAV |
Beacon’s uplift is the key driver this quarter, but Spurs’s size – and its dual programme cadence (Phase I/II Parkinson’s initiation in CY2026 and Gaucher Phase III pivotal completion targeted H1 CY2028) – underlines its importance to medium-term NAV.
Governance and near-term events to watch
- Circular next week: proposals for a new Investment Policy and details of SIML’s new long-term incentive arrangements.
- General Meeting: early March 2026 to approve the proposals.
- Capital Markets Day: 19 March 2026 – portfolio and market outlook update from the SIML team and portfolio company management.
My take: a constructive quarter, with catalysts lining up
This was a clean, confidence-building update. A 3.6% NAV per share rise is solid in context, Beacon’s oversubscribed round is a strong external signal, and the capital pool remains healthy after meaningful deployment. The pipeline is now set up for four shots on goal in 2026 – Autolus commercial traction, Beacon pivotal data, and readouts at iOnctura and Resolution.
On the flip side, Quell’s delay pushes a potential 2026 catalyst into 2027, and the usual biotech risks apply – clinical, regulatory and market. Still, Syncona’s hands-on approach and concentration in companies approaching or in late-stage development is exactly how you create NAV torque when the cycle turns.
The headline to watch is the proposed return of a minimum of £250 million to shareholders, which hinges on approval of the new Investment Objective and Policy. If market conditions continue to thaw and the 2026 milestones deliver, the setup for NAV growth – and capital returns – looks increasingly compelling.
